186 related articles for article (PubMed ID: 34725042)
21. Bevacizumab, irinotecan, temozolomide, tyrosine kinase inhibition, and MEK inhibition are effective against pleomorphic xanthoastrocytoma regardless of V600E status.
Thompson EM; Landi D; Ashley D; Keir ST; Bigner D
J Neurooncol; 2018 Nov; 140(2):261-268. PubMed ID: 30120661
[TBL] [Abstract][Full Text] [Related]
22. Combined "Infiltrating Astrocytoma/Pleomorphic Xanthoastrocytoma" Harboring IDH1 R132H and BRAF V600E Mutations.
Yamada S; Kipp BR; Voss JS; Giannini C; Raghunathan A
Am J Surg Pathol; 2016 Feb; 40(2):279-84. PubMed ID: 26414224
[TBL] [Abstract][Full Text] [Related]
23. Pleomorphic xanthoastrocytoma in the brainstem with BRAF V600E mutation: A case report.
Guo Y; Ning G; Feng M; Qu HB
Asian J Surg; 2023 Aug; 46(8):3371-3373. PubMed ID: 36977615
[No Abstract] [Full Text] [Related]
24. Cerebellar Pleomorphic Xanthoastrocytoma with BRAF V600E Mutation.
Kim SH; Hwang K; Lee KS; Choe G; Kim CY
World Neurosurg; 2020 Jul; 139():577-581. PubMed ID: 32348888
[TBL] [Abstract][Full Text] [Related]
25. Immunohistochemistry is highly sensitive and specific for detection of BRAF V600E mutation in pleomorphic xanthoastrocytoma.
Ida CM; Vrana JA; Rodriguez FJ; Jentoft ME; Caron AA; Jenkins SM; Giannini C
Acta Neuropathol Commun; 2013 May; 1():20. PubMed ID: 24252190
[TBL] [Abstract][Full Text] [Related]
26. BRAF V600E mutations are frequent in dysembryoplastic neuroepithelial tumors and subependymal giant cell astrocytomas.
Lee D; Cho YH; Kang SY; Yoon N; Sung CO; Suh YL
J Surg Oncol; 2015 Mar; 111(3):359-64. PubMed ID: 25346165
[TBL] [Abstract][Full Text] [Related]
27. A novel, potentially targetable TMEM106B-BRAF fusion in pleomorphic xanthoastrocytoma.
Hsiao SJ; Karajannis MA; Diolaiti D; Mansukhani MM; Bender JG; Kung AL; Garvin JH
Cold Spring Harb Mol Case Stud; 2017 Mar; 3(2):a001396. PubMed ID: 28299358
[TBL] [Abstract][Full Text] [Related]
28. BRAF V600E mutation: A treatable driver mutation in pleomorphic xanthoastrocytoma (PXA).
Hofer S; Berthod G; Riklin C; Rushing E; Feilchenfeldt J
Acta Oncol; 2016; 55(1):122-3. PubMed ID: 25811650
[No Abstract] [Full Text] [Related]
29. Successful Treatment of a Progressive BRAF V600E-Mutated Anaplastic Pleomorphic Xanthoastrocytoma With Vemurafenib Monotherapy.
Lee EQ; Ruland S; LeBoeuf NR; Wen PY; Santagata S
J Clin Oncol; 2016 Apr; 34(10):e87-9. PubMed ID: 25092772
[No Abstract] [Full Text] [Related]
30. Primary Meningeal Pleomorphic Xanthoastrocytoma With Anaplastic Features: A Report of 2 Cases, One With BRAF(V600E) Mutation and Clinical Response to the BRAF Inhibitor Dabrafenib.
Usubalieva A; Pierson CR; Kavran CA; Huntoon K; Kryvenko ON; Mayer TG; Zhao W; Rock J; Ammirati M; Puduvalli VK; Lehman NL
J Neuropathol Exp Neurol; 2015 Oct; 74(10):960-9. PubMed ID: 26352988
[TBL] [Abstract][Full Text] [Related]
31. MR Imaging of Pediatric Low-Grade Gliomas: Pretherapeutic Differentiation of
Trasolini A; Erker C; Cheng S; Crowell C; McFadden K; Moineddin R; Sargent MA; Mata-Mbemba D
AJNR Am J Neuroradiol; 2022 Aug; 43(8):1196-1201. PubMed ID: 35863783
[TBL] [Abstract][Full Text] [Related]
32. BRAF inhibition with concomitant tumor treating fields for a multiply progressive pleomorphic xanthoastrocytoma.
Lukas RV; Merrell RT
CNS Oncol; 2018 Apr; 7(2):CNS10. PubMed ID: 29708404
[TBL] [Abstract][Full Text] [Related]
33. The genetic landscape of anaplastic pleomorphic xanthoastrocytoma.
Phillips JJ; Gong H; Chen K; Joseph NM; van Ziffle J; Bastian BC; Grenert JP; Kline CN; Mueller S; Banerjee A; Nicolaides T; Gupta N; Berger MS; Lee HS; Pekmezci M; Tihan T; Bollen AW; Perry A; Shieh JTC; Solomon DA
Brain Pathol; 2019 Jan; 29(1):85-96. PubMed ID: 30051528
[TBL] [Abstract][Full Text] [Related]
34. Activating NRF1-BRAF and ATG7-RAF1 fusions in anaplastic pleomorphic xanthoastrocytoma without BRAF p.V600E mutation.
Phillips JJ; Gong H; Chen K; Joseph NM; van Ziffle J; Jin LW; Bastian BC; Bollen AW; Perry A; Nicolaides T; Solomon DA; Shieh JT
Acta Neuropathol; 2016 Nov; 132(5):757-760. PubMed ID: 27624885
[No Abstract] [Full Text] [Related]
35. [BRAF V600E mutation and clinicopathologic characteristics in 250 cases of brain tumors associated with epilepsy].
Qi XL; Yao K; Duan ZJ; Bian Y; Ma Z; Piao YS; Gong LP
Zhonghua Bing Li Xue Za Zhi; 2018 Sep; 47(9):664-670. PubMed ID: 30220118
[No Abstract] [Full Text] [Related]
36. BRAF-Mutated Pleomorphic Xanthoastrocytoma of the Spinal Cord with Eventual Anaplastic Transformation.
Hong CS; Wang JL; Dornbos D; Joehlin-Price A; Elder JB
World Neurosurg; 2017 Feb; 98():871.e9-871.e15. PubMed ID: 27956254
[TBL] [Abstract][Full Text] [Related]
37. Clinical neuropathology practice news 2-2012: BRAF V600E testing.
Capper D; Berghoff AS; von Deimling A; Preusser M
Clin Neuropathol; 2012; 31(2):64-6. PubMed ID: 22385786
[TBL] [Abstract][Full Text] [Related]
38. Sustained Response to Targeted Therapy in a Patient With Disseminated Anaplastic Pleomorphic Xanthoastrocytoma.
Amayiri N; Swaidan M; Al-Hussaini M; Halalsheh H; Al-Nassan A; Musharbash A; Tabori U; Hawkins C; Bouffet E
J Pediatr Hematol Oncol; 2018 Aug; 40(6):478-482. PubMed ID: 29200156
[TBL] [Abstract][Full Text] [Related]
39. Clinicopathological and genetic association between epithelioid glioblastoma and pleomorphic xanthoastrocytoma.
Furuta T; Miyoshi H; Komaki S; Arakawa F; Morioka M; Ohshima K; Nakada M; Sugita Y
Neuropathology; 2018 Jun; 38(3):218-227. PubMed ID: 29532523
[TBL] [Abstract][Full Text] [Related]
40. BRAF/MEK Dual Inhibitors Therapy in Progressive and Anaplastic Pleomorphic Xanthoastrocytoma: Case Series and Literature Review.
Kata K; Rodriguez-Quintero JC; Arevalo OD; Zhang JJ; Bhattacharjee MB; Ware C; Dono A; Riascos-Castaneda R; Tandon N; Blanco A; Esquenazi Y; Ballester LY; Amsbaugh M; Day AL; Zhu JJ
J Natl Compr Canc Netw; 2022 Nov; 20(11):1193-1202.e6. PubMed ID: 36351333
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
